Quantification of SMN mRNA or protein levels has served as the most commonly used molecular biomarker of SMA, but it does not necessarily correlate with disease severity and may not reliably reflect disease progression (Sumner et al., 2006; Wadman et al., 2016). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.